Single CRISPR infusion lowers cholesterol for a year in early trial
A first-in-human Phase 1 trial tested a one-time CRISPR-Cas9 infusion called CTX310 in 15 patients with lipid disorders that had resisted standard treatment. At the highest dose, LDL cholesterol fell by 52.5% and triglycerides by 47.8% after 12 months. No serious side effects tied to the therapy were reported during that year.
CTX310 is a one-time CRISPR-Cas9 infusion designed to reach the liver and disable ANGPTL3, a gene involved in regulating circulating fats. In this first-in-human Phase 1 study, 15 patients with lipid disorders poorly controlled by standard medicines received doses from 0.1 to 0.8 mg/kg after corticosteroid and antihistamine pretreatment.
At the top dose, LDL cholesterol dropped 52.5% and triglycerides 47.8% at 12 months. No therapy-related serious adverse events occurred during that year. Results were presented in 2026 and published in NEJM; safety follow-up is planned for 15 years.
If confirmed in larger trials, a one-time therapy could offer an alternative for people whose lipid disorders resist standard treatment, potentially improving convenience and long-term cardiovascular risk management. It may also raise questions about affordability, access, and the burden of 15-year safety monitoring. Because only 15 patients were studied, broader effects on clinical practice and public health remain uncertain and should be interpreted cautiously.